KDIGO AKI Staging
ورودیهای بالینی بیمار
حداقل ۰.۲ — حداکثر ۱۵ • واحد: mg/dL
حداقل ۰.۲ — حداکثر ۲۰ • واحد: mg/dL
حداقل ۰ — حداکثر ۱۰ • واحد: mg/dL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- No AKI0–0
- Stage 11–1
- Stage 22–2
- Stage 33–3
The KDIGO AKI Staging calculates estimating glomerular filtration rate (eGFR), staging renal disease, and adjusting drug clearances. Key inputs include baseline scr. Scores guide adjusting renal medication clearance, coordinating nephrology follow-up, or planning renal replacement therapy. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
KDIGO acute kidney injury staging (2012) from serum creatinine change and urine output: Stage 1 (SCr 1.5-1.9× baseline or ≥0.3 mg/dL rise; UO <0.5 mL/kg/h for 6-12 h), Stage 2 (SCr 2.0-2.9×; UO <0.5 for ≥12 h), Stage 3 (SCr 3.0× or ≥4.0 mg/dL or RRT; UO <0.3 for ≥24 h or anuria ≥12 h). Stage = worst of the creatinine and urine-output criteria.
Clinical Indication
The KDIGO AKI Staging is indicated for bedside clinical practice to support KDIGO acute kidney injury staging (2012) from serum creatinine change and urine output: Stage 1 (SCr 1.5-1.9× baseline or ≥0.3 mg/dL rise; UO <0.5 mL/kg/h for 6-12 h), Stage 2 (SCr 2.0-2.9×; UO <0.5 for ≥12 h), Stage 3 (SCr 3.0× or ≥4.0 mg/dL or RRT; UO <0.3 for ≥24 h or anuria ≥12 h). Stage = worst of the creatinine and urine-output criteria.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute kidney injury (AKI), chronic kidney disease stages 1-5, or acid-base and fluid-electrolyte disturbances. Clinical application is indicated across Nephrology clinics, hemodialysis units, acute inpatient renal services, and metabolic wards.
Limitations & Contraindications
eGFR estimation equations assume steady-state serum creatinine and become unreliable during unstable AKI, amputations, or extremes of muscle mass.
Clinical Pearls & Action Plan
Serum creatinine lags behind acute reductions in glomerular filtration; monitor hourly urine output and consider cystatin C in evolving AKI.
Stage = max(creatinine stage, urine-output stage) per KDIGO thresholds
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| baseline_scr | float | Yes | Baseline serum creatinine(mg/dL) |
| current_scr | float | Yes | Current serum creatinine(mg/dL) |
| rise_48h | float | No | Absolute rise within 48 h (optional; ≥0.3 qualifies Stage 1)(mg/dL) |
| uo_category | string | No | Lowest qualifying urine-output category observed |
| on_rrt | string | No | Renal replacement therapy initiated |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | No AKI | No AKI |
| 1–1 | Stage 1 | Stage 1 |
| 2–2 | Stage 2 | Stage 2 |
| 3–3 | Stage 3 | Stage 3 |
Evidence-Based References (EBM)
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1-138.